FIELD: medicine, neurology. SUBSTANCE: in exacerbation period patient is subjected for plasmapheresis and additional cryoplasma sorption is carried out also. In the first seance of plasmapheresis heparinized plasma is removed at amount 11-12 ml/1 kg body mass of patient followed by substitution of circulating plasma volume with crystalloid solution at the same volume. Obtained plasma is frozen at -20 C and in 48 h cryoplasma sorption of removed plasma is carried out. To this time plasmapheresis is carried out again and heparinized plasma is removed at amount 17-17.5 ml/1 kg body mass of patient and deficiency of circulating plasma volume is compensated with autoplasma obtained in the 1-st plasmapheresis seance and subjected for cryoplasma sorption. The remained deficiency of circulating plasma volume is compensated with crystalloid solution. Plasma taken repeatedly is subjected for freezing again at -20 C and in 48 h cryoplasma sorption of removed plasma is carried out and the third seance of plasmapheresis is carried out in volume 23-24 ml/1 kg body mass of patient. Formed deficiency of circulating plasma volume is compensated with autoplasma obtained in the second seance of cryoplasma sorption and the remained part - with crystalloid solution. Obtained plasma is subjected for cryoplasma sorption in 48 h and after finishing this period the 4-th seance of plasma-pheresis is carried out and plasma is removed at amount 23-24 ml/1 kg body mass of patient. Formed deficiency of circulating plasma volume is compensated completely with autoplasma obtained in the 3-d seance of cryoplasma sorption. Plasma obtained at the 4-th seance is subjected for cryoplasma sorption and recovered to patient by intravessel administration at discrete regime for 24 h. EFFECT: enhanced effectiveness of treatment, accelerated neurological disorders arresting in exacerbation period of cerebrospinal sclerosis. 2 tbl, 1 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF EXTRACORPORAL PLASMA BLOOD MODIFICATION BEFORE ITS REINFUSION | 1995 |
|
RU2113239C1 |
CEREBRAL ATHEROSCLEROSIS TREATMENT METHOD | 2000 |
|
RU2195321C2 |
METHOD OF PREVENTING THROMBOTIC COMPLICATIONS OF ATHEROSCLEROSIS | 1996 |
|
RU2141843C1 |
METHOD FOR TREATING PYO-INFLAMMATORY DISEASES | 1999 |
|
RU2170591C1 |
METHOD OF HEPATITIS TYPE C TREATMENT | 2006 |
|
RU2336096C1 |
METHOD OF TREATMENT OF DOUDEANAL ULCER | 1996 |
|
RU2141830C1 |
METHOD FOR TREATING SEVERE PYOINFLAMMATORY DISEASES | 1999 |
|
RU2176527C2 |
METHOD FOR TREATING ACUTE INFLAMMATORY DISEASES OF FEMALE INTERNAL GENITALIA | 1997 |
|
RU2142821C1 |
METHOD OF TREATING CHRONIC INFLAMMATORY DISEASES OF INTERNAL GENITAL ORGANS IN FEMALES | 1997 |
|
RU2153892C2 |
METHOD OF TREATMENT OF PAIN SYNDROME | 2001 |
|
RU2208437C2 |
Authors
Dates
2000-01-10—Published
1997-03-26—Filed